SCIANDRA, FRANCESCA
SCIANDRA, FRANCESCA
Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" - SCITEC
3D Graphene Scaffolds for Skeletal Muscle Regeneration: Future Perspectives
2020 Palmieri V.; Sciandra F.; Bozzi M.; De Spirito M.; Papi M.
3D-printed graphene polylactic acid devices resistant to SARS-CoV-2: Sunlight-mediated sterilization of additive manufactured objects
2022 De Maio, F; Rosa, E; Perini, G; Augello, A; Niccolini, B; Ciaiola, F; Santarelli, G; Sciandra, F; Bozzi, M; Sanguinetti, M; Sali, M; De Spirito, M; Delogu, G; Palmieri, V; Papi, M
?-Dystroglycan hypoglycosylation affects cell migration by influencing ?-dystroglycan membrane clustering and filopodia length: A musticale confocal microscopi analysis
2017 Palmieri, V; Bozzi, M; Signorino, G; Papi, M; De Spirito, M; Brancaccio, A; Maulucci, G; Sciandra, F
A dystroglycan mutation (p.Cys667Phe) associated to muscle-eye-brain disease with multicystic leucodystrophy results in ER-retention of the mutant protein.
2018 Signorino, Giulia; Covaceuszach, Sonia; Bozzi, Manuela; Hubner, Wolfgang; Monkemoller, Viola; Konarev Petr, V; Cassetta, Alberto; Brancaccio, Andrea; Sciandra, Francesca
A dystroglycan mutation (p.Cys66uPhe) associated to muscle-eye-brain disease with multicystic leukodystrophy results in ER-retention of the mutant protein
2018 Signorino, G; Covaceuszach, S; Bozzi, M; Hübner, W; Mönkemöller, V; Konarev, Pv; Cassetta, A; Brancaccio, A; Sciandra, F
A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core portein in some, but not all, dystroglycanopathy patients
2015 L Humphrey, E; Lacey, E; Le, Lt; Feng, L; Sciandra, F; Morris, Cr; Hewitt, Je; Holt, I; Brancaccio, A; Barresi, R; A Sewry, C; Brown, Sc; Morris, Ge
A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein in some, but not all, dystroglycanopathy patients
2015 Humphrey Emma, L; Lacey, Erica; Le Lam, T; Feng, Lucy; Sciandra, Francesca; Morris Charlotte, R; Hewitt Jane, E; Holt, Ian; Holt, Ian; Brancaccio, Andrea; Barresi, Rita; Sewry Caroline, A; Sewry Caroline, A; Brown Susan, C; Morris Glenn, E; Morris Glenn, E
A primary dystroglycanopathy causing muscle-eye-brain disease with multicystic leukodystrophy: from cellular and biochemical analysis to a mouse model
2019 Francesca Sciandra; Manuela Bozzi; Maria Giulia Bigotti; Alberto Cassetta; Sonia Covaceuszach; Wolfgang Hübner; Thomas Huser; CarolAnn Eberle; Natalia Niemir; Sandra Blaess; Andrea Brancaccio
A second Ig-like domain identified in dystroglycan by molecular modelling and dynamics
2011 DE ROSA, MARIA CRISTINA; Pirolli, Davide; Bozzi, Manuela; Sciandra, Francesca; Giardina, Bruno; Brancaccio, Andrea
A synthetic peptide corresponding to the 550-585 region of alpha-dystroglycan binds beta-dystroglycan as revealed by NMR spectroscopy.
2001 Bozzi M; Veglia G; Paci M; Sciandra F; Giardina B; Brancaccio A.
Activation of muscle-specific receptor tyrosine kinase and binding to dystroglycan are regulated by alternative mRNA splicing of agrin
2006 Scotton, P; Bleckmann, D; Stebler, M; Sciandra, F; Brancaccio, A; Meier, T; Stetefeld, J; Ruegg, Ma
Alpha Dystroglycan monoclonal antibodies
2013 Humphrey, E; Lacey, E; Brown, S; Sewry, C; Brancaccio, A; Sciandra, F; Morris, Ge
alpha-Dystroglycan does not play a major pathogenic role in autosomal recessive hereditary inclusion-body myopathy
2005 Broccolini, A; Gliubizzi, C; Pavoni, E; Gidaro, T; Morosetti, R; Sciandra, F; Giardina, B; Tonali, P; Ricci, E; Brancaccio, A; Mirabella, M
Alpha-Dystroglycan is a potential target of matrix metalloproteinase MMP-2
2014 Sbardella, D; Sciandra, F; Gioia, M; Marini, S; Gori, A; Giardina, B; Coletta, M; Brancaccio, A; Bozzi, M
Alpha-dystroglycan is a potential target of matrix metalloproteinase MMP-2
2015 Sbardella, D; Sciandra, F; Gioia, M; Marini, S; Gori, A; Giardina, B; Tarantino, U; Coletta, M; Brancaccio, A; Bozzi, M
An immunological analysis of dystroglycan subunits: lessons learned from a small cohort of non-congenital dystrophic patients.
2011 Pavoni, Ernesto; Sciandra, Francesca; Tasca, Giorgio; Tittarelli, Roberta; Bozzi, Manuela; Giardina, Bruno; Ricci, Enzo; Brancaccio, Andrea
Analisi strutturale e funzionale dei domini del distroglicano: ruolo per la stabilità del muscolo e aspetti fisiopatologici
2014 Bozzi, M; Sciandra, F; Delli Paoli, E; Signorino, G; Giardina, B; Bigotti, Mg; Brancaccio, A
Analysis at the molecular level of the interaction between alfa-dystroglycan and beta-dystroglycan
2005 Brancaccio A; Sciandra F; Bozzi M; Pavoni E; Ferri L;Giardina; B Scientific
Analysis at the molecular level of the interaction between ±-dystroglycan and ²-dystroglycan and assessment of its implication for skeletal muscle physiopathology
2009 Sciandra F.; Morlacchi S.; Desimio M.G.; Giardina B.; Bozzi M.; Brancaccio A.
Analysis of dystroglycan in human patients affected by neuromuscular disorders.Analysis of dystroglycan in human patients affected by neuromuscular disorders
2007 Sciandra F.; Pavoni E.; Bozzi M.; Ricci E.; Brancaccio A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 3D Graphene Scaffolds for Skeletal Muscle Regeneration: Future Perspectives | 1-gen-2020 | Palmieri V.; Sciandra F.; Bozzi M.; De Spirito M.; Papi M. | |
| 3D-printed graphene polylactic acid devices resistant to SARS-CoV-2: Sunlight-mediated sterilization of additive manufactured objects | 1-gen-2022 | De Maio, F; Rosa, E; Perini, G; Augello, A; Niccolini, B; Ciaiola, F; Santarelli, G; Sciandra, F; Bozzi, M; Sanguinetti, M; Sali, M; De Spirito, M; Delogu, G; Palmieri, V; Papi, M | |
| ?-Dystroglycan hypoglycosylation affects cell migration by influencing ?-dystroglycan membrane clustering and filopodia length: A musticale confocal microscopi analysis | 1-gen-2017 | Palmieri, V; Bozzi, M; Signorino, G; Papi, M; De Spirito, M; Brancaccio, A; Maulucci, G; Sciandra, F | |
| A dystroglycan mutation (p.Cys667Phe) associated to muscle-eye-brain disease with multicystic leucodystrophy results in ER-retention of the mutant protein. | 1-gen-2018 | Signorino, Giulia; Covaceuszach, Sonia; Bozzi, Manuela; Hubner, Wolfgang; Monkemoller, Viola; Konarev Petr, V; Cassetta, Alberto; Brancaccio, Andrea; Sciandra, Francesca | |
| A dystroglycan mutation (p.Cys66uPhe) associated to muscle-eye-brain disease with multicystic leukodystrophy results in ER-retention of the mutant protein | 1-gen-2018 | Signorino, G; Covaceuszach, S; Bozzi, M; Hübner, W; Mönkemöller, V; Konarev, Pv; Cassetta, A; Brancaccio, A; Sciandra, F | |
| A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core portein in some, but not all, dystroglycanopathy patients | 1-gen-2015 | L Humphrey, E; Lacey, E; Le, Lt; Feng, L; Sciandra, F; Morris, Cr; Hewitt, Je; Holt, I; Brancaccio, A; Barresi, R; A Sewry, C; Brown, Sc; Morris, Ge | |
| A new monoclonal antibody DAG-6F4 against human alpha-dystroglycan reveals reduced core protein in some, but not all, dystroglycanopathy patients | 1-gen-2015 | Humphrey Emma, L; Lacey, Erica; Le Lam, T; Feng, Lucy; Sciandra, Francesca; Morris Charlotte, R; Hewitt Jane, E; Holt, Ian; Holt, Ian; Brancaccio, Andrea; Barresi, Rita; Sewry Caroline, A; Sewry Caroline, A; Brown Susan, C; Morris Glenn, E; Morris Glenn, E | |
| A primary dystroglycanopathy causing muscle-eye-brain disease with multicystic leukodystrophy: from cellular and biochemical analysis to a mouse model | 1-gen-2019 | Francesca Sciandra; Manuela Bozzi; Maria Giulia Bigotti; Alberto Cassetta; Sonia Covaceuszach; Wolfgang Hübner; Thomas Huser; CarolAnn Eberle; Natalia Niemir; Sandra Blaess; Andrea Brancaccio | |
| A second Ig-like domain identified in dystroglycan by molecular modelling and dynamics | 1-gen-2011 | DE ROSA, MARIA CRISTINA; Pirolli, Davide; Bozzi, Manuela; Sciandra, Francesca; Giardina, Bruno; Brancaccio, Andrea | |
| A synthetic peptide corresponding to the 550-585 region of alpha-dystroglycan binds beta-dystroglycan as revealed by NMR spectroscopy. | 1-gen-2001 | Bozzi M; Veglia G; Paci M; Sciandra F; Giardina B; Brancaccio A. | |
| Activation of muscle-specific receptor tyrosine kinase and binding to dystroglycan are regulated by alternative mRNA splicing of agrin | 1-gen-2006 | Scotton, P; Bleckmann, D; Stebler, M; Sciandra, F; Brancaccio, A; Meier, T; Stetefeld, J; Ruegg, Ma | |
| Alpha Dystroglycan monoclonal antibodies | 1-gen-2013 | Humphrey, E; Lacey, E; Brown, S; Sewry, C; Brancaccio, A; Sciandra, F; Morris, Ge | |
| alpha-Dystroglycan does not play a major pathogenic role in autosomal recessive hereditary inclusion-body myopathy | 1-gen-2005 | Broccolini, A; Gliubizzi, C; Pavoni, E; Gidaro, T; Morosetti, R; Sciandra, F; Giardina, B; Tonali, P; Ricci, E; Brancaccio, A; Mirabella, M | |
| Alpha-Dystroglycan is a potential target of matrix metalloproteinase MMP-2 | 1-gen-2014 | Sbardella, D; Sciandra, F; Gioia, M; Marini, S; Gori, A; Giardina, B; Coletta, M; Brancaccio, A; Bozzi, M | |
| Alpha-dystroglycan is a potential target of matrix metalloproteinase MMP-2 | 1-gen-2015 | Sbardella, D; Sciandra, F; Gioia, M; Marini, S; Gori, A; Giardina, B; Tarantino, U; Coletta, M; Brancaccio, A; Bozzi, M | |
| An immunological analysis of dystroglycan subunits: lessons learned from a small cohort of non-congenital dystrophic patients. | 1-gen-2011 | Pavoni, Ernesto; Sciandra, Francesca; Tasca, Giorgio; Tittarelli, Roberta; Bozzi, Manuela; Giardina, Bruno; Ricci, Enzo; Brancaccio, Andrea | |
| Analisi strutturale e funzionale dei domini del distroglicano: ruolo per la stabilità del muscolo e aspetti fisiopatologici | 1-gen-2014 | Bozzi, M; Sciandra, F; Delli Paoli, E; Signorino, G; Giardina, B; Bigotti, Mg; Brancaccio, A | |
| Analysis at the molecular level of the interaction between alfa-dystroglycan and beta-dystroglycan | 1-gen-2005 | Brancaccio A; Sciandra F; Bozzi M; Pavoni E; Ferri L;Giardina; B Scientific | |
| Analysis at the molecular level of the interaction between ±-dystroglycan and ²-dystroglycan and assessment of its implication for skeletal muscle physiopathology | 1-gen-2009 | Sciandra F.; Morlacchi S.; Desimio M.G.; Giardina B.; Bozzi M.; Brancaccio A. | |
| Analysis of dystroglycan in human patients affected by neuromuscular disorders.Analysis of dystroglycan in human patients affected by neuromuscular disorders | 1-gen-2007 | Sciandra F.; Pavoni E.; Bozzi M.; Ricci E.; Brancaccio A. |